Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | EO2401 |
Trade Name | |
Synonyms | EO 2401|EO-2401 |
Drug Descriptions |
EO2401 is a cancer vaccine comprising microbiome-derived peptides that are similar to IL13Ralpha2, BIRC5, and FOXM1, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2034-2034). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C16564 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + EO2401 + Nivolumab | Bevacizumab EO2401 Nivolumab | 0 | 0 |
EO2401 | EO2401 | 0 | 1 |
EO2401 + Nivolumab | EO2401 Nivolumab | 0 | 1 |